文献速递新发突发、热带与寄生虫病

儿童季节性接种RTS,S/AS01E疟疾疫苗后的抗环子孢子蛋白抗体应答

The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.
PubMed 文献 · Clin Infect Dis · 2022-01-01

在非洲儿童试验中,季节性接种RTS,S/AS01E疫苗联合季节性疟疾化学预防较任一单独干预降低无并发症和重症疟疾发病率。本文报告该试验中儿童对季节性RTS,S/AS01E接种的抗环子孢子蛋白抗体应答:3剂基础免疫后抗体滴度高(几何平均滴度368.9酶联免疫吸附试验单位/mL),但首次加强前下降;年度加强针应答强但低于基础系列,且第二针低于第一针(几何平均升高比值0.66,95%CI 0.57-0.77);抗体应答上三分位儿童次年疟疾发病率低于最低三分位(HR 0.43,95%CI 0.28-0.66)。

要点

  • 3剂基础免疫后抗环子孢子蛋白抗体应答强,几何平均滴度368.9酶联免疫吸附试验单位/mL,但首次加强前滴度下降。
  • 年度加强针抗体应答低于基础系列,第二针低于第一针(几何平均升高比值0.66,95%CI 0.57-0.77)。
  • 抗体应答上三分位儿童次年疟疾发病率低于最低三分位(HR 0.43,95%CI 0.28-0.66)。

核心结论

  • 季节性接种RTS,S/AS01E诱导强的加强抗体应答,第二针加强后应答低于第一针。
  • 第二针加强后抗体应答减弱未伴随效力减弱。

研究设计与样本

  • 本报告基于非洲儿童试验,随机选取部分儿童,采集RTS,S/AS01E三剂基础免疫前和1个月后、以及两剂季节性加强前和1个月后的血清。
  • 采用酶联免疫吸附试验检测抗环子孢子蛋白抗体,并探讨接种后抗体滴度与疟疾发病率的关系。

主要发现

  • 3剂基础免疫后抗环子孢子蛋白抗体应答强,几何平均滴度368.9酶联免疫吸附试验单位/mL,但首次加强前滴度下降。
  • 每年疟疾传播季前加强针抗体应答强,但低于基础免疫系列,且第二针低于第一针(几何平均升高比值0.66,95%CI 0.57-0.77)。
  • 接种后抗体应答上三分位儿童次年疟疾发病率低于最低三分位儿童(HR 0.43,95%CI 0.28-0.66)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A trial in African children showed that combining seasonal vaccination with the RTS,S/AS01E vaccine with seasonal malaria chemoprevention reduced the incidence of uncomplicated and severe malaria compared with either intervention given alone. Here, we report on the anti-circumsporozoite antibody response to seasonal RTS,S/AS01E vaccination in children in this trial. METHODS: Sera from a randomly selected subset of children collected before and 1 month after 3 priming doses of RTS,S/AS01E and before and 1 month after 2 seasonal booster doses were tested for anti-circumsporozoite antibodies using enzyme-linked immunosorbent assay. The association between post-vaccination antibody titer and incidence of malaria was explored. RESULTS: A strong anti-circumsporozoite antibody response to 3 priming doses of RTS,S/AS01E was seen (geometric mean titer, 368.9 enzyme-linked immunosorbent assay units/mL), but titers fell prior to the first booster dose. A strong antibody response to an annual, pre-malaria transmission season booster dose was observed, but this was lower than after the primary vaccination series and lower after the second than after the first booster dose (ratio of geometric mean rise, 0.66; 95% confidence interval [CI], .57-.77). Children whose antibody response was in the upper tercile post-vaccination had a lower incidence of malaria during the following year than children in the lowest tercile (hazard ratio, 0.43; 95% CI, .28-.66). CONCLUSIONS: Seasonal vaccination with RTS,S/AS01E induced a strong booster antibody response that was lower after the second than after the first booster dose. The diminished antibody response to the second booster dose was not associated with diminished efficacy. CLINICAL TRIALS REGISTRATION: NCT03143218.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sagara I, Zongo I, Cairns M, et al. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clin Infect Dis. 2022. PMID: 34894221. doi:10.1093/cid/ciab1017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。